Total Payments
$5,271
2024 Payments
$335.44
Companies
39
Transactions
335
Medicare Patients
1,603
Medicare Billing
$218,825
Payment Breakdown by Category
Food & Beverage$5,065 (96.1%)
Education$206.14 (3.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,065 | 332 | 96.1% |
| Education | $206.14 | 3 | 3.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | $890.09 | 105 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $715.07 | 36 | $0 (2023) |
| GENZYME CORPORATION | $583.14 | 28 | $0 (2022) |
| TG Therapeutics, Inc. | $341.97 | 6 | $0 (2024) |
| ABBVIE INC. | $297.00 | 22 | $0 (2024) |
| UCB, Inc. | $273.44 | 16 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $253.03 | 6 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $236.23 | 8 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $229.86 | 21 | $0 (2020) |
| Avanir Pharmaceuticals, Inc. | $203.32 | 14 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $335.44 | 8 | TG Therapeutics, Inc. ($270.51) |
| 2023 | $256.80 | 10 | TG Therapeutics, Inc. ($71.46) |
| 2022 | $385.91 | 26 | ABBVIE INC. ($132.56) |
| 2021 | $392.09 | 17 | Janssen Pharmaceuticals, Inc ($138.26) |
| 2020 | $659.13 | 38 | Supernus Pharmaceuticals, Inc. ($319.08) |
| 2019 | $982.61 | 80 | Supernus Pharmaceuticals, Inc. ($317.57) |
| 2018 | $1,298 | 101 | Novartis Pharmaceuticals Corporation ($310.19) |
| 2017 | $961.60 | 55 | Teva Pharmaceuticals USA, Inc. ($222.94) |
All Payment Transactions
335 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $110.29 | General |
| Category: Immunology | ||||||
| 09/24/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $105.03 | General |
| Category: Immunology | ||||||
| 09/17/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $9.51 | General |
| Category: Immunology | ||||||
| 08/23/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: NEUROSCIENCE | ||||||
| 08/20/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $23.15 | General |
| Category: Immunology | ||||||
| 07/12/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $25.53 | General |
| Category: NEUROSCIENCE | ||||||
| 05/13/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $22.53 | General |
| Category: Immunology | ||||||
| 04/26/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: NEUROSCIENCE | ||||||
| 12/18/2023 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $71.46 | General |
| Category: Immunology | ||||||
| 06/20/2023 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Neurology | ||||||
| 03/24/2023 | Eisai Inc. | Fycompa (Drug) | Food and Beverage | Cash or cash equivalent | $26.75 | General |
| Category: Neurology | ||||||
| 03/23/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: Rare Disease | ||||||
| 03/20/2023 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: Neurology | ||||||
| 02/07/2023 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: Immunology | ||||||
| 02/07/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Neurology | ||||||
| 01/24/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $19.90 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 01/04/2023 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $20.65 | General |
| Category: NEUROLOGY | ||||||
| 01/04/2023 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Neurology | ||||||
| 12/14/2022 | Lilly USA, LLC | EMGALITY (Drug), REYVOW | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Neuroscience | ||||||
| 12/08/2022 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: NEUROSCIENCE | ||||||
| 12/01/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $11.95 | General |
| Category: NEUROSCIENCE | ||||||
| 11/29/2022 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: NEUROSCIENCE | ||||||
| 11/17/2022 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: UPLIZNA | ||||||
| 11/15/2022 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: Neurology | ||||||
| 10/28/2022 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $16.72 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 121 | 176 | $39,305 | $12,787 |
| 2022 | 5 | 431 | 732 | $175,485 | $60,678 |
| 2021 | 6 | 491 | 780 | $188,965 | $68,417 |
| 2020 | 5 | 560 | 821 | $201,850 | $76,944 |
Total Patients
1,603
Total Services
2,509
Medicare Billing
$218,825
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 50 | 98 | $18,130 | $5,628 | 31.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 29 | 29 | $11,020 | $3,765 | 34.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 17 | $4,760 | $1,572 | 33.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 13 | $2,925 | $1,158 | 39.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 13 | 19 | $2,470 | $664.38 | 26.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 175 | 368 | $82,800 | $27,913 | 33.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 115 | 118 | $44,840 | $17,465 | 38.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 99 | 203 | $37,555 | $10,825 | 28.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 28 | 29 | $6,090 | $2,289 | 37.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 14 | 14 | $4,200 | $2,185 | 52.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 197 | 406 | $91,350 | $31,313 | 34.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 113 | 113 | $42,940 | $16,614 | 38.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 86 | 157 | $29,045 | $8,490 | 29.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 33 | 39 | $11,700 | $6,498 | 55.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 50 | 51 | $10,710 | $3,937 | 36.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 12 | 14 | $3,220 | $1,565 | 48.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 212 | 395 | $88,875 | $31,597 | 35.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 127 | 130 | $49,400 | $20,175 | 40.8% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 49 | 61 | $18,300 | $10,386 | 56.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 101 | 163 | $30,155 | $8,938 | 29.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 71 | 72 | $15,120 | $5,847 | 38.7% |
About Dr. Joshua Neucks, MD
Dr. Joshua Neucks, MD is a Neurology healthcare provider based in Danville, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/11/2009. The National Provider Identifier (NPI) number assigned to this provider is 1265675953.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joshua Neucks, MD has received a total of $5,271 in payments from pharmaceutical and medical device companies, with $335.44 received in 2024. These payments were reported across 335 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($5,065).
As a Medicare-enrolled provider, Neucks has provided services to 1,603 Medicare beneficiaries, totaling 2,509 services with total Medicare billing of $218,825. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Danville, IN
- Active Since 04/11/2009
- Last Updated 09/25/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1265675953
Products in Payments
- TROKENDI XR (Drug) $521.65
- OXTELLAR XR (Drug) $368.44
- AUBAGIO (Drug) $344.78
- BRIUMVI (Drug) $341.97
- GILENYA (Drug) $244.71
- APTIOM (Drug) $229.86
- Briviact (Drug) $227.92
- NUEDEXTA (Drug) $203.32
- XARELTO (Drug) $201.88
- LEMTRADA (Drug) $196.76
- UBRELVY (Drug) $180.85
- SOLIRIS (Drug) $134.54
- AIMOVIG (Biological) $127.04
- VNS Therapy (Device) $119.57
- TYSABRI (Biological) $97.26
- KESIMPTA (Drug) $85.30
- BOTOX (Biological) $79.67
- MAYZENT (Drug) $71.35
- BOTOX THERAPEUTIC (Biological) $51.25
- UPLIZNA (Drug) $46.98
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Danville
Dr. Anne Morse, Do, DO
Neurology — Payments: $431,331
Neurology $431,331
Dr. Justin Chandler, Md, MD
Neurology — Payments: $50,350
Neurology $50,350
Dr. Said Ibrahimi, M.d, M.D
Neurology — Payments: $37,110
Neurology $37,110
Victor Owusu-Yaw, M.d, M.D
Neurology — Payments: $22,929
Neurology $22,929
Jesse Li, Md, MD
Neurology — Payments: $9,520
Neurology $9,520
Prateeka Koul, Md, MD
Neurology — Payments: $3,815
Neurology $3,815